Cellectis S.A.: Bpifrance Participations SA amends Schedule 13D stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Bpifrance Participations SA amended its Schedule 13D filing on Cellectis S.A., updating its disclosed stake in the French gene-editing biotech. The amended filing carries SEC accession number 0001104659-26-124483. The change in the state-owned investor's position matters because Bpifrance is a significant backer of Cellectis, and Schedule 13D amendments signal shifts in ownership or intent by large holders. Investors will watch for further filings or disclosures clarifying whether the adjustment reflects a purchase, sale or other change in Bpifrance's holdings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.
Named in this story
Bpifrance Participations SA, Cellectis S.A.